Zusammenfassung
Hintergrund: Die hepatozellulären Karzinome zählen weltweit zu den häufigsten soliden Tumorentitäten.
Aufgrund des bei Diagnosestellung häufig bereits fortgeschrittenen Tumorstadiums ist
eine Tumorresektion als kurative Behandlungsoption in vielen Fällen nicht mehr möglich.
Daher kommt der Überprüfung alternativer Behandlungsmethoden, die beispielsweise die
spätere Resektion zunächst nicht resektabler Tumoren ermöglichen könnten sowie der
Verbesserung der vorhandenen palliativen Behandlungsoptionen große Bedeutung zu. Fallbericht: Bei einer 77-jährigen Patientin wurde im August 2003 eine rasch progrediente Raumforderung
im Bereich beider Leberlappen diagnostiziert. Der Befund war aufgrund der Tumorgröße
lokal inoperabel, sodass von September bis Oktober 2003 eine hyperfraktioniert akzelerierte
Radiotherapie der 2 gut abgrenzbaren Raumforderungen (Segmente IV und V) bis zu einer
Gesamtdosis von 55,0 Gy durchgeführt wurde (Einzeldosis: 1,2 Gy / 1,3 Gy, 2 × täglich,
12 Fraktionen / Woche, Gesamtbehandlungszeit: 27 Tage). Ergebnisse: Trotz des großen Zielvolumens im Bereich der Leber (ca. 50 % des gesamten Lebervolumens)
bei ausgedehntem HCC und initial symptomatischer Zielsetzung, konnte in diesem Einzelfall
durch die Radiotherapie, bei guter Toleranz der Behandlung, eine kurative Resektabilität
des Tumors mit späterer R 0-Leberteilresektion im Intervall von 9 Monaten erreicht
werden.
Abstract
Background: Hepatocellular carcinomas are among the most frequent solid tumour entities worldwide.
Because of the advanced tumour stage frequently observed at diagnosis a tumour resection
as a curative treatment option is often impossible. Therefore the consideration of
alternative treatment methods (possibly enhancing the chance of a subsequent tumour
resection) and the improvement of existing palliative treatment options are gaining
considerable importance. Case report: A 77-years-old female patient was diagnosed to have a rapidly progredient expansion
in the liver in August 2003. Due to its large extension a local tumour resection was
impossible and therefore a hyperfractionated accelerated radiotherapy up to a total
dose of 55.0 Gy (single dose 1.2 Gy / 1.3 Gy 2 daily fractions, 12 fractions per week,
overall treatment time: 27 days) was applied to both well-definable expansions (segments
IV and V) from September to October 2003. Results: Despite the large target volume (about 50 % of the total liver volume) at an extended
HCC and considering the fact that initially symptomatic treatment was aimed at, a
curative tumour resectability with subsequent R 0 partial liver resection at an interval
of 9 months could be achieved by means of radiotherapy treatment.
Schlüsselwörter
Hepatozelluläres Karzinom - Strahlentherapie - akzelerierte Hyperfraktionierung
Key words
hepatocellular carcinoma - radiation therapy - accelerated hyperfractionation
Literatur
1
Bismuth H, Fecteau A.
Combination therapy in oncology - hepatocellular carcinoma.
Chirurg.
1998;
69
360-365
2
Bruix J, Sherman M, Llovet J M. et al .
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000
EASL conference. European Association for the Study of the Liver.
J Hepatol.
2001;
35
421-430
3
Brunner T B, Schwab D, Meyer T. et al .
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic
biliary carcinoma. A retrospective analysis.
Strahlenther Onkol.
2004;
180
751-757
4
Camma C, Schepis F, Orlando A. et al .
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis
of randomized controlled trials.
Radiology.
2002;
224
47-54
5
Cheng J C, Wu J K, Huang C M. et al .
Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and
intensity-modulated radiation therapy for patients with hepatocellular carcinoma and
radiation-induced liver disease.
Int J Radiat Oncol Biol Phys.
2003;
56
229-234
6
Dawson L A, McGinn C J, Normolle D. et al .
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for
unresectable intrahepatic malignancies.
J Clin Oncol.
2000;
18
2210-2218
7
Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire .
A comparison of lipiodol chemoembolization and conservative treatment for unresectable
hepatocellular carcinoma.
N Engl J Med.
1995;
332
1256-1261
8
Guo W J, Yu E X.
Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular
carcinoma.
Br J Radiol.
2000;
73
1091-1097
9
Guo W J, Yu E X, Liu L M. et al .
Comparison between chemoembolization combined with radiotherapy and chemoembolization
alone for large hepatocellular carcinoma.
World J Gastroenterol.
2003;
9
1697-1701
10
Hawkins M A, Dawson L A.
Radiation therapy for hepatocellular carcinoma - from palliation to cure.
Cancer.
2006;
106
1653-1663
11
Kato H, Tsujii H, Miyamoto T. et al .
Results of the first prospective study of carbon ion radiotherapy for hepatocellular
carcinoma with liver cirrhosis.
Int J Radiat Oncol Biol Phys.
2004;
59
1468-1476
12
Lau W Y, Leung T W, Leung K L. et al .
Cytoreductive surgery for hepatocellular carcinoma.
Surg Oncol.
1994;
3
161-166
13
Lencioni R, Cioni D, Donati F. et al .
Combination of interventional therapies in hepatocellular carcinoma.
Hepatogastroenterology.
2001;
48
8-14
14
Lencioni R A, Allgaier H P, Cioni D. et al .
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency
thermal ablation versus percutaneous ethanol injection.
Radiology.
2003;
228
235-240
15
Lin S M, Lin C J, Lin C C. et al .
Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular
carcinoma ≤ 4 cm.
Gastroenterology.
2004;
127
1714-1723
16
Livraghi T.
Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis.
Hepatogastroenterology.
2001;
48
20-24
17
Livraghi T, Goldberg S N, Lazzaroni S. et al .
Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.
Radiology.
2000;
214
761-768
18
Llovet J M, Bruix J.
Systematic review of randomized trials for unresectable hepato-cellular carcinoma:
Chemoembolization improves survival.
Hepatology.
2003;
37
429-442
19
Llovet J M, Bustamante J, Castells A. et al .
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the
design and evaluation of therapeutic trials.
Hepatology.
1999;
29
62-67
20
Llovet J M, Fuster J, Bruix J.
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:
resection versus transplantation.
Hepatology.
1999;
30
1434-1440
21
Llovet J M, Real M I, Montana X. et al .
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients
with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet.
2002;
359
1734-1739
22
Llovet J M, Vilana R, Bru C. et al .
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single
hepatocellular carcinoma.
Hepatology.
2001;
33
1124-1129
23
Otsuka M, Ohara K, Takada Y. et al .
Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular
carcinoma.
Int J Clin Oncol.
2003;
8
151-155
24
Park H C, Seong J, Han K H. et al .
Dose-response relationship in local radiotherapy for hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys.
2002;
54
150-155
25
Poon R T, Fan S T, Lo C M. et al .
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term
results of treatment and prognostic factors.
Ann Surg.
1999;
229
216-222
26
Poon R T, Ng K K, Lam C M. et al .
Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than
3 cm in diameter.
Arch Surg.
2004;
139
281-287
27
Ricke J, Wust P, Stohlmann A. et al .
CT-gesteuerte Brachytherapie - Eine neue perkutane Technik zur interstitiellen Ablation
von Lebermetastasen.
Strahlenther Onkol.
2004;
180
274-280
28
Ruzzenente A, Manzoni G D, Molfetta M. et al .
Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation.
World J Gastroenterol.
2004;
10
1137-1140
29
Schleicher U M, Staatz G, Alzen G. et al .
Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors.
Strahlenther Onkol.
2002;
178
682-687
30
Seong J, Park H C, Han K H. et al .
Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular
carcinoma: a retrospective study of 158 patients.
Int J Radiat Oncol Biol Phys.
2003;
55
329-336
31
Seong J, Park H C, Han K H. et al .
Clinical results of 3-dimensional conformal radiotherapy combined with transarterial
chemoembolization for hepatocellular carcinoma in the cirrhotic patients.
Hepatol Res.
2003 b;
27
30-35
32
Taouli B, Goh J SK, Lu Y. et al .
Growth rate of hepatocellular carcinoma. Evaluation with serial computed tomography
or magnetic resonance imaging.
J Comput Assist Tomogr.
2005;
29
425-429
33
Tokuuye K, Sumi M, Kagami Y. et al .
Radiotherapy for hepatocellular carcinoma.
Strahlenther Onkol.
2000;
176
406-410
34
Wada H, Takai Y, Nemoto K. et al .
Univariate analysis of factors correlated with tumor control probability of three-dimensional
conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors.
Int J Radiat Oncol Biol Phys.
2004;
58
1114-1120
35
Wulf J, Hädinger U, Oppitz U. et al .
Stereotactic radiotherapy of targets in the lung and liver.
Strahlenther Onkol.
2001;
177
645-655
Dr. F. Friedrich
Klinik und Poliklinik für Strahlentherapie und Radioonkologie · Universitätsklinikum
Leipzig AöR
Stephanstraße 9 a
04103 Leipzig
Phone: +49/3 41/9 71 84 00
Fax: +49/3 41/9 71 84 09
Email: franziska.friedrich@medizin.uni-leipzig.de